Original Report

Impact of inpatient radiation on length of stay and health care costs


 

Background Health care costs are rising. Identifying areas for health care utilization savings may reduce costs.

Objective To identify oncology patients receiving inpatient radiotherapy with the purpose of measuring length of stay (LoS) and hospital charges.

Methods During July 2013 the oncology service physicians at Mount Sinai Medical Center in New York City were surveyed daily to identify patients receiving inpatient radiation. Actual LoS, acuity LoS were determined from the chart review. Expected LoS was calculated using the University Healthsystem Consortium database. Charges associated with actual LoS, acuity LoS, and expected LoS were then reported. Actual and expected LoS were compared for inpatient radiotherapy and nonradiotherapy groups.

Results 7 patients were identified as having remained in the hospital to receive radiation treatment. In that cohort, the average actual LoS and charges per patient were 40.1 and $48,724, compared with acuity LoS and charges of 25.6 days and $34,089 and expected LoS and charges of 7.7 days and $10,028. Mean LoS and charges attributed to radiation alone amounted to 11 days and $12,514. The mean actual LoS of oncology patients admitted during the same time period who did not receive radiation was 6.7 days, compared with 40.1 days for patients who received radiation (P < .0001).

Limitations Inability to access actual reimbursement data prevented exact cost calculations, small sample size, and single-institution focus.

Conclusion Delivery of radiation therapy during inpatient hospitalization extends LoS and contributes to higher health care costs. Methods to facilitate the delivery of outpatient radiotherapy may result in cost savings.

Click on the PDF icon at the top of this introduction to read the full article.

Recommended Reading

Prolonged zoledronic acid-induced hypocalcemia in hypercalcemia of malignancy
MDedge Hematology and Oncology
NCCN unveils 'Evidence Blocks' to facilitate treatment discussions
MDedge Hematology and Oncology
Dexamethasone reduces radiation therapy–induced pain flare
MDedge Hematology and Oncology
FDA finds long-term clopidogrel does not increase death or cancer risks
MDedge Hematology and Oncology
Survivors of childhood cancers at increased risk for autoimmune diseases
MDedge Hematology and Oncology
Suicide rate high in patients with head and neck cancer
MDedge Hematology and Oncology
ACS: Watchful waiting for some rectal cancers almost ready for ‘prime time’
MDedge Hematology and Oncology
Balancing clinical and supportive care at every step of the disease continuum
MDedge Hematology and Oncology
A modified olanzapine regimen for the prevention of chemotherapy-induced nausea and vomiting
MDedge Hematology and Oncology
Caregivers’ attitudes toward promoting exercise among patients with late-stage lung cancer
MDedge Hematology and Oncology